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When Peter Beighton (PB) took up a fellowship at the Johns 
Hopkins University Hospital in 1968 -1969, with Dr Victor 
McKusick, the 4th edition of Heritable Disorders of Connective 
Tissue was in preparation.[1] PB had already concluded that Ehlers-
Danlos syndrome (EDS) was a group of disorders with distinct but 
overlapping phenotypes and genotypes.[2] McKusick[1] extensively 
acknowledged the contribution which PB had made to delineating 
the heterogeneity in EDSs in Chapter 6. In Chapter 7 of the same 
volume, McKusick reviewed the knowledge about osteogenesis 
imperfecta (OI) and noted that ‘the exceptionally wide range of 
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expressivity in OI may be but different 
expressions of a single type of connective 
tissue disorder, inherited as a Mendelian 
autosomal dominant disorder. However, 
the existence of an infrequent autosomal 
recessive form … is quite certain’.
Genetic heterogeneity in OI
1975 - 1980
David Danks (DMD) asked me, in 1974, 
to undertake a study in Victoria, Australia, 
to clarify the genetic relationship between 
perinatally lethal cases of OI and families 
with clearly autosomal dominant inheritance. 
He had preceded PB at Johns Hopkins, with 
Victor McKusick, by several years and was 
very aware of PB’s contribution to unravelling 
the genetic heterogeneity in EDSs. Like 
PB, DMD had undertaken a population 
study of skeletal dysplasias in Victoria, 
Australia (1971 - 1973), and recognised 
the considerable heterogeneity in these 
disorders. Commencing in 1975, an attempt 
was made to ascertain all patients with OI 
in Victoria, including all deaths from OI 
over a 30-year period. The study proceeded 
along the lines of two former studies, one 
by Seedorf[3] in Denmark and the other by 
Smars[4] in Sweden in 1965. We undertook 
careful pedigree-taking and analysis. The 
outcome was that in Victoria in 1977, not only 
had we documented a significant number 
of pedigrees with autosomal dominant 
inheritance of OI with distinctly blue sclerae 
but we also had many families with pedigree 
evidence of autosomal recessive inheritance. 
These included a perinatally lethal group as 
well as a group with progressive deformity 
of long bones and spine. In the face of 
compelling population genetic evidence for 
both autosomal recessively inherited forms of 
OI, as well as dominantly inherited types of 
OI, we reached the conclusion that there had 
to be locus heterogeneity.[5,6] The question 
then was how much genetic heterogeneity 
was there? Recent studies have characterised 
22 gene loci in which mutations result in 
various types of OI (Table 1).[7,8] The relative 
prevalence of mutations in different genes 
might therefore be reflected in a different 
prevalence of various types of OI in distinct 
human populations. As early as 1993, Wallis, 
Beighton and colleagues[9] had concluded 
that autosomal recessive forms of OI were 
the most prevalent forms of OI in southern 
Africa and segregation of OI in these families 
was not linked to type I collagen genes. This 
one observation sustained future research in 
autosomal recessive forms of OI worldwide 
for a considerable period.
The heritable disorders of 
connective tissue
In the preface to his 1978 monograph 
Inherited Disorders of the Skeleton, PB noted 
that ‘in the period 1971 - 1976 more than 
1 000 patients with disorders of the skeleton 
had been investigated in genetic clinics in 
southern Africa’.[10] While there were already 
several atlases of skeletal dysplasia such 
as the Atlas of Constitutional Disorders of 
Skeletal Development in 1974,[11] this 1978 
publication by PB represented a significant, 
new and different contribution that 
integrated the skeletal dysplasias within the 
broad spectrum of the heritable disorders of 
connective tissue (HDCT). Indeed, various 
meetings of the International Nosology 
Committee for Constitutional Disorders 
of the Skeleton had struggled with the 
need to be inclusive, particularly in the 
differential diagnosis of anomalies found in 
the skeleton. Some anomalies, e.g. Wormian 
bones, were found in distinctly different 
disorders across the spectrum of the HDCT. 
A joint decision was made in convening the 
1986 International Nosology of Heritable 
Disorders of Connective Tissue to cover 
all those disorders that were not already 
in the International Skeletal Dysplasia 
Nomenclature and Classification, except 
for certain specific groups of disorders.[12] 
The marked overlap between the clinical 
findings in the OI syndromes and other 
HDCT was noted. This was particularly 
evident in the overlap in features seen in 
patients with OI with features in common 
with the EDSs, such as marked joint 
hypermobility, bruising, occasional skin 
fragility and even rare manifestations such 
as elastosis perforans serpinginosa. The 
1978 Inherited Disorders of the Skeleton by 
PB was so important because it reminded 
geneticists that, as a group, HDCT were 
not so very rare. The monograph provided 
information important to the ‘trainee and 
practising doctors, with easily accessible 
and authoritative information about genetic 
aspects of their specialities’.
PB noted the genetic heterogeneity in OI 
with particular reference to southern Africa 
and, in fact, before the 1979 paper from 
Victoria was published, again reinforcing the 
potential for genetic locus heterogeneity in 
the OI syndromes.[6]
PB and Anne de Paepe convened the 
International Nosology of Heritable Disorders 
of Connective Tissue in Berlin in 1986.[12] 
Already, very significant progress had been 
made since 1970. This Berlin nosology 
attempted to delineate and characterise the 
individual heritable disorders of connective 
tissue and provide key phenotypic features 
to differentiate each of the disorders. It 
was recognised at the time and had been 
discussed that the four broad groups of OI 
type were each genetically heterogeneous. 
Two further types of OI had been postulated 
(but not included in the nomenclature) – 
an autosomal dominant disorder associated 
with/characterised by a tendency to hyper-
plastic callus (now known as OI type 5) 
and an X-linked form of OI which was 
rare and at that time defined only by its 
pedigree features, but now known to result 
from hemizygous mutations in Plastin 3 
(PLS3).[7,13]
1986 - 1999
In 1986, there were still some groups who 
questioned the genetic heterogeneity in OI 
and felt that sibling recurrence could be 
explained by germinal mosaicism, which 
had been recently discovered in families 
with sibling recurrence of OI.[14] By the early 
1990s, this was reinforced by the discovery 
of heterozygous mutations in siblings with 
perinatally lethal OI but clinically unaffected 
parents. PB, on the other hand, was quite 
gracious and kept an open mind about 
autosomal recessive inheritance. He provided 
the full pedigrees of two families, which were 
incorporated in a publication on autosomal 
recessive OI type 3, published from our 
research group in 1986.[15] These pedigrees 
were by no means meant to represent 
complete population ascertainment, but they 
reinforced the existence in southern Africa of 
Table 1. The OI nomenclature 2015 – International Nomenclature Committee for 
Constitutional Disorders of the Skeleton
Syndrome name Subtype Equivalent numerical type
Classic non-deforming OI (with blue sclerae) 2 1
Common variable OI (with normal sclerae) 10 4
OI with calcification in interosseous membranes 1 5
Progressively deforming OI with normal sclerae 17 3
Perinatally lethal OI 5 2
In addition, there are at least nine named syndromes and multiple premature ageing
disorders with overlap in phenotypic features with OI
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families where the evidence strongly suggested an autosomal recessive 
pattern of inheritance.[16]
OI with congenital joint contractures, the Bruck 
syndromes and endogamy
The 1989 article with Dennis Viljoen reported five individuals with 
OI with a distinct phenotype comprising congenital contractures 
of the joints together with OI, and named this disorder Bruck 
syndrome (BS).[17] In the article, the first two affected children were 
singletons whereas there were three children affected in family 3. 
These patients were from the Tswana tribal group, the Pedi tribal 
group and the Shona tribal group of Zimbabwe. Consanguinity was 
not present. However, an increased prevalence in certain indigenous 
groups suggested endogamy and an increased frequency of a founder 
mutation for BS. The report of the proband in family 3 in the paper 
noted that he had contractures with joint webbing at the elbow and 
knee joints, together with talipes equinovarus. Patient 2 in family 3 
is illustrated showing quite marked joint webbing. Further families 
were reported but the first report of a unifying defect came from 
studies of telopeptide lysyl hydroxylases in the laboratory of Dr Ruud 
Bank.[18] This identified missense mutations in procollagen-lysine 
2-oxoglutarate 5-dioxygenase (PLOD2) in two families, one of which 
was from our Australian research cohort.[19] Previous families with 
BS had been studied by linkage analysis and this had mapped the BS 
locus to an 18-centimorgan region on chromosome 17p12. However, 
other families were linked to 3q23-q24 and, in these, the deficiency in 
PLOD2 was confirmed. It was almost a further decade before the study 
of four inbred Turkish families from the Black Sea region located the 
other form of OI with congenital joint contractures, to homozygous 
mutations in FKBP10 that encode the RER protein FKBP65.[20] BS 
type 1 mutations in FKBP10 appear to be a far more common cause 
of BS in some populations.[21] There is a high prevalence of BS in the 
Samoan Islands, where Tim Cundy was able to ascertain 17 affected 
individuals from 10 families homozygous for the mutation c.948dupT, 
p.Ile317Tyrfs*56. It is interesting that two families from among the SA 
Venda tribal group had the c.831dupC mutation, which was also found 
in a Saudi family.[22] The extent of carrier frequency for mutations in 
FKBP10 remains to be published, but what is clear is that mutations in 
FKBP10 may have quite a variable phenotype. Individuals have now 
been reported with homozygous FKBP10 mutation with only bone 
fragility and without congenital contractures.[21]
An ocular type of OI
Ingrid Winship, PB and colleagues[23] reported an ocular form 
of OI with putative autosomal recessive inheritance, in 1986. 
The paper reported a bone fragility disorder in an inbred Indian 
family, with two uncles and a nephew with newborn presentation 
with ocular involvement and recurrent fractures commencing in 
mid to late childhood. The report is extensively illustrated with 
skeletal radiographs showing slender long bones and generalised 
platyspondyly. Eye findings included bilateral corneal opacities and 
white sclerae.
Frontali et al.[24]  in 1985 had reported siblings with osteoporosis 
pseudoglioma (OPPG) syndrome, in which there was severe 
osteoporosis and sclerae of normal hue but with progressive eye 
involvement. PB replied to the letter to the editor that ‘the question 
of syndromic identity will ultimately be resolved at the molecular 
level’.[25]
A majority of OPPG cases (typical cases) have loss of function 
mutations in low-density lipoprotein receptor-related protein 5 
(LRP5). However, in a significant number of patients, no mutation 
in LRP5 was detected. In 2001, Schmidt et al.[26] reported on a 
consanguineous Turkish family with almost complete platyspondyly/
vertebral flattening retinal detachment, cataract, and facial 
dysmorphism. A further affected child in a non-consanguineous 
Turkish family was reported in 2006.[27] This child presented with 
fractures at birth. Recent whole exome screening in a further family 
with spondylo-ocular dysplasia revealed a homozygous mutation 
in xylose transferase 2 (XYLT2).[28] Both siblings were identified 
prenatally because of the detection of widened nuchal folds. These 
siblings were noted to have nystagmus soon after birth and early-
onset symptomatic osteoporosis with progressive vertebral collapse 
(interpreted as platyspondyly, hence ‘spondylodysplasia’). While 
vertebral findings were progressive and quite severe, requiring 
treatment with cyclic intravenous pamidronate, long-bone fractures 
were rare. During the investigations of this family, a further single 
case in a consanguineous family, also with generalised osteoporosis 
and marked vertebral flattening, was also found to be homozygous 
for a different mutation in XYLT2. Two of the three patients had 
retinal detachments. There is variability in the phenotypic features 
reported for the patients with a spondylo-ocular syndrome. However, 
it is important to note that, in addition, hearing loss and heart defects 
have been noted in a number of these patients.
At the present time, there is no overall review specifically dealing 
with the patterns of visual disability and eye pathology in OPPG 
v. spondylo-ocular syndrome(s). Improved phenotype/genotype 
correlation will be available in the future, resulting from multiple 
parallel sequencing for both the classic and typical OPPG and these 
other patients with early-onset eye involvement and progressive 
osteoporosis, such as this spondylo-ocular group. Spondylo-ocular is 
an unfortunate name for this particular syndrome as the generalised 
platyspondyly is thought to be due to early-onset progressive 
osteoporosis. In patients with homozygous LRP mutations, there was 
a wide variety of eye involvement. Some patients were congenitally 
blind in both eyes, and some blind in one eye and visually impaired 
in the other, or moderately visually impaired in both eyes. Most 
adults were blind by 15 years of age and all were blind by 25 years 
of age. The eye findings in OPPG included isolated cataracts, 
retinal coloboma, Peters anomaly and unilateral eye involvement. In 
addition, these patients may develop severe vitreoretinal findings, 
including phthisis bulbi. In the few patients to date reported with 
a proven or with possible homozygosity for XYLT2, eye findings 
include early amblyopia, cataract and progress to retinal detachment 
in late childhood or the second decade.
The characterisation of this mutation in XYLT2 provides 
important biochemical and functional insight into the role of the 
enzymes involved in the biosynthesis of the GAG linker region. 
These are known as GAG linkeropathies and involve mutations 
which disrupt the synthesis of a tetrasaccharide – xylose-galactose-
galactose-glucuronic acid, O-linked to the proteoglycan core 
protein. Mutations in xylose transferase 1 result in the newborn 
skeletal dysplasia Desbuquois dysplasia type 2, in which patients 
develop a progressive joint hypermobility and dislocatibility. Short 
stature is not necessary present in patients with spondylo-ocular 
syndrome due to homozygous mutations in XYLT2. Trunk height 
may be reduced but falls overall in the low-normal range. The 
inborn errors of the biosynthetic enzymes responsible for the GAG 
linkeropathies are summarised in Fig. 1. A second linkeropathy, 
spondyloepipmetaphyseal dysplasia with joint laxity (SEMDJL) 
(Beighton-type) was described by Beighton and Kozlowski[29] in 
1980. In a subsequent paper, PB[30] reviewed the findings in a 
series of 18 cases followed for more than decade. Joint laxity was 
especially striking in the hands. Mutations in B3GALT6 result in 
a pleiotropic connective tissue disorder.[31] Not only are features 
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of joint hypermobility present, but there 
is a wide spectrum of findings including 
skin fragility, intellectual disability and 
a spondyloepimetaphyseal dysplasia 
with bone fragility. Kyphoscoliosis had 
been reported in the initial description, 
resulting in thoracic asymmetry, restrictive 
lung disease, respiratory failure and early 
death. PB subsequently reported that 
severe thoracic deformity was refractory to 
treatment and external bracing was usually 
ineffective. Survival beyond the early adult 
years was reduced.
Mutations in B4GALT7 (MIM 604327), a 
galactosyltransferase responsible for adding 
galactose to the O-linked xylose, results in a 
similar disorder to SEMDJL but with clinical 
features of EDS and premature ageing.
Contributions of Africa and 
the Middle East to advancing 
knowledge of genetic heterogeneity 
in OI
More than any others, two papers have 
encouraged researchers to look beyond 
mutations in the two types I collagen genes 
as the cause of the clinical and radiographic 
heterogeneity in OI. These two papers by 
PB and colleagues have sustained research 
interest in pursuing molecular genetics 
studies in families in whom type 1 collagen 
mutations have been excluded either by linkage 
or by molecular DNA sequencing.[9,32] In the 
second paper, PB and Versfeld noted the 
paradoxically high frequency of autosomal 
recessive OI type 3 in a hospital clinic 
survey of black patients with OI. While 
studies in hospital patients always run the 
risk of a major ascertainment bias, this 
sample is reflected in further studies in 
the southern African population indicating 
that autosomal recessive forms of OI are 
more common than the classic autosomal 
dominant OI type 1. BS has also been 
reported in high frequency in various tribes 
in southern African including the Tswana, 
Pedi and Shona tribe. Mutations in FKBP10 
have been confirmed in patients with BS 
in the Venda tribe.[17] FKBP10 is now the 
second-most common gene identified as 
a cause of OI in diverse populations. It 
was first localised and characterised as a 
cause of OI in the Turkish population. 
Common mutations are shared between 
the Arabian Peninsula and southern Africa. 
What was not understood initially is a 
considerable variability between and within 
families segregating mutations in FKBP10. 
Joint contractures may not be congenital but 
patients may still segregate osteoporosis and 
progressive pelvic deformity (progressive 
protusio acetabula).[21] Furthermore, there 
may be very variable expressivity, with 
the first fractures occurring as late as the 
teenage years. Classic molecular genetic 
sequencing was used to define a common 
mutation in LEPRE1 in American blacks 
with origins in West Africa. This has led 
to confirmation of a raised heterozygous 
frequency for LEPRE1 mutation in those 
populations.[33]
International conferences on the 
nosology of constitutional disorders 
of the skeleton
An international nomenclature for constitu-
tional (intrinsic) diseases of bone was 
convened as early as 1969, following a 
meeting of paediatric radiologists in Warsaw. 
The initial committee meeting was held in 
Paris and presented its final report at the 
European Society of Paediatric Radiology 
in 1970. This became known as the Paris 
Nomenclature. Sufficient progress had been 
made by 1992 to convene a second revision 
which was attended by PB and 12 other 
experts. This second revision of the nosology 
grouped morphologically similar disorders, 
concluding that this classification would 
facilitate the recognition of specific entities. 
In setting out the international classification, 
the international working group on this 
occasion provided tabulation for mode of 
inheritance, chromosomal localisation, the 
responsible gene and the affected protein. [34] 
Very little was known at the time; in fact, 
the genetic basis of only 30 of the 300 
entities listed was known. This is in striking 
contrast to the report of the 2015 revision 
of the Nosology and Classification of Genetic 
Skeletal Disorders, where there are some 
430 entit ies, of which 423 now have a 
known molecular genetic basis.[8] PB was 
also a founding member of the International 
Skeletal Dysplasia Society (ISDS) which 
held its first conference in the Children’s 
Memorial Hospital, Chicago on 17 June 
1993. His contribution to the delineation 
of the genetic skeletal dysplasias has been 
truly remarkable. At the first meeting of the 
ISDS he gave a presentation on ‘Familial Hip 
Joint Dysplasia’. It must be very gratifying to 
him that the molecular defect in Beukes hip 
dysplasia was recently demonstrated to result 
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Fig. 1. The linkeropathies, modified after Fig. 1 in Malfait et al.[31] (courtesy of Fransiska Malfait).
Fig. 2. PB contributing with Gen Nishimura to 
the discussion at the 5th International Nosology 
Meeting, ISDS, Martigny, Switzerland, 2005 
(courtesy of Andrea Superti-Furga).
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from mutations in the ubiquitin-fold modifier 1-specific peptidase 2 
gene, UFSP2.[35]
PB made many contributions to the nosology meetings and the 
meetings of the ISDS. His contributions were highly respected by all. 
He made a memorable contribution to the meeting in Martigny in 2005 
against the backdrop of the French Alps, contributing to the vigorous 
debate (Fig. 2).
Where are we now with OI? By 2015, it had been confirmed 
that there are three patterns of Mendelian inheritance – autosomal 
dominant, autosomal recessive and X-linked recessive. The 
International Nomenclature Committee for Cons titutional Disorders 
of the Skeleton has strong ly proposed that, at the present time, 
the OI disorders be grouped into five major phenotypic groups 
(Table 1) known by characteristic names but also numbered by 
Arabic numerals. Twenty-two genes are now known in which 
mutations result in at least one of these five phenotypes (Table 2) or 
a special syndrome of OI plus other features. OI type 5, the disorder 
of OI with calcification of interosseous membranes, is the only one 
of the phenotypes at present known to result from mutations in just 
one gene, IFITM5.
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